Angelman syndrome (AS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 to 2030

Indication name: Angelman syndrome (AS)

Angelman syndrome (AS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Angelman syndrome (AS) is a rare neuro-genetic disorder, Thelansis estimated that disease occurs in one in 15,000 live births or 500,000 people worldwide. Angelman syndrome is estimated to be out of total US population, people affected by Angelman syndrome are 28,404.

In most cases of Angelman syndrome, these genetic changes appear to occur randomly (sporadically) but in about 3-5% they can be inherited. In approximately 70-75 percent of cases there is a microdeletion of region 15q11-13 of the maternally-derived chromosome 15 that includes deletion of the UBE3A gene.

In about 1 percent of cases, a deletion of this chromosomal region may occur due to a complex chromosomal rearrangement, in which a segment of chromosome 15 breaks off and moves to another chromosomal location. Approximately 2-5 percent of Angelman syndrome cases are caused by uniparental disomy, an abnormality in which a person receives both copies of a chromosome from one parent instead of receiving one from each parent.

KOLs insights of Angelman syndrome (AS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of Angelman syndrome (AS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Angelman syndrome (AS) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Angelman syndrome (AS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 to 2030

S. No        Asset        Company                      Stage

1        GTX-102                GeneTX Biotherapeutics, LLC        Phase 2

2        RO7248824          Hoffmann-La Roche Phase 1

3        Gaboxadol       Ovid Therapeutics Inc. Phase 3

4        Circadin             Neurim Pharmaceuticals Ltd. Phase 3

5        NNZ-2591        Neuren Pharmaceuticals Ltd Phase 1